A synthetic bispecific antibody that binds to p53 R175H, activating T cells to kill tumor cells developed by Hsiue et al. was effective at lysing tumor cells both in vitro and in vivo in animal models36, and a phase I/II clinical trial (PYNNACLE) evaluating the efficacy of PC14586, a p53 reactivator developed by PMV Pharmaceuticals that is selective for p53 Y220C, alone and in combination with pembrolizumab is currently underway37. The gene discussed is TP53; the disease is neoplasm.